Schaper Benz & Wise Investment Counsel’s Teva Pharmaceuticals TEVA Stock Holding History

Schaper Benz & Wise Investment Counsel’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,660	Closed	-$306K	–	99
2016 Q3	$306K	Hold	6,660	–	–	0.05%	93
2016 Q2	$335K	Hold	6,660	–	–	0.06%	87
2016 Q1	$356K	Hold	6,660	–	–	0.07%	84
2015 Q4	$437K	Hold	6,660	–	–	0.09%	81
2015 Q3	$376K	Sell	6,660 -300	-4%	-$19.5K	0.08%	82
2015 Q2	$411K	Sell	6,960 -2,300	-25%	-$142K	0.08%	83
2015 Q1	$577K	Sell	9,260 -4,860	-34%	-$283K	0.11%	77
2014 Q4	$812K	Sell	14,120 -3,850	-21%	-$214K	0.16%	74
2014 Q3	$966K	Sell	17,970 -3,884	-18%	-$206K	0.2%	70
2014 Q2	$1.15M	Sell	21,854 -8,176	-27%	-$418K	0.24%	67
2014 Q1	$1.59M	Sell	30,030 -67,695	-69%	-$3.13M	0.34%	58
2013 Q4	$3.92M	Sell	97,725 -43,436	-31%	-$1.71M	0.87%	43
2013 Q3	$5.33M	Sell	141,161 -6,850	-5%	-$267K	1.24%	36
2013 Q2	$5.8M	Buy	+148,011	New	+$5.76M	1.43%	35

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Schaper Benz & Wise Investment Counsel's TEVA Position: Q4 2016 in Review

Schaper Benz & Wise Investment Counsel sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 6,660 shares — an estimated $306K sold.

Schaper Benz & Wise Investment Counsel first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $5.8M in Q2 2013. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Schaper Benz & Wise Investment Counsel reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Schaper Benz & Wise Investment Counsel sold 6,660 Teva Pharmaceuticals shares in Q4 2016, an estimated $306K.
Schaper Benz & Wise Investment Counsel first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Schaper Benz & Wise Investment Counsel's Teva Pharmaceuticals position peaked at $5.8M in Q2 2013.
738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Schaper Benz & Wise Investment Counsel's 13F filing for Q4 2016, filed 30 Jan 2017.